Intellia Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $9,111 | $6,957 | $28,935 | $-1,917 |
Gross Profit | 9,111 | 4,358 | 26,423 | -4,383 |
EBITDA | -142,162 | -136,444 | -111,491 | -137,426 |
EBIT | -144,770 | -139,043 | -114,003 | -139,892 |
Net Income | -135,712 | -146,975 | -107,436 | -132,161 |
Net Change In Cash | 9,111 | 6,957 | 28,935 | -1,917 |
Free Cash Flow | -86,116 | -59,198 | -123,168 | -94,574 |
Cash | 120,495 | 130,848 | 171,979 | 226,748 |
Basic Shares | 101,002 | 96,975 | 95,502 | 90,461 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $36,275 | $52,121 | $33,053 | $57,994 |
Gross Profit | -398,794 | 44,549 | 33,053 | 57,994 |
EBITDA | -506,315 | -450,592 | -260,959 | -130,272 |
EBIT | -515,291 | -458,164 | -267,850 | -136,583 |
Net Income | -481,192 | -490,208 | -259,718 | -125,568 |
Net Change In Cash | 36,275 | 52,121 | 33,053 | 57,994 |
Cost of Revenue | 409,977 | -39,120 | 107,380 | |
Free Cash Flow | -408,071 | -391,677 | -237,786 | -53,497 |
Cash | 226,748 | 523,506 | 123,406 | 160,020 |
Basic Shares | 88,770 | 76,972 | 70,894 | 55,987 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$1.34 |
2024-06-30 | -$1.52 |
2024-03-31 | -$1.12 |
2023-12-31 | -$1.46 |
